Merck KGaA, SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
8don MSN
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback